Citations

Clear

152 citation(s) found for "Tobin, M D".

Radiographic Determinants of Serum Neurofilament Light Chain Elevation in Multiple Sclerosis (P8-19.002)
Schleiss, Katherine, Chouhdry, Hira , Morris, Pearse, Baker, Matthew, Tobin, W., Flanagan, Eoin , Kantarci, Orhun, Keegan, Mark , Soldan, M. Paz, Pittock, Sean, banks, Samantha, Flanagan, Eoin P. , Kantarci, Orhun H. , Soldán, M. Mateo Paz , Pittock, Sean J.

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000216614 Get It

Tumefactive Demyelination at Multiple Sclerosis Onset Associates With Less Severe Long-term Disability (P4-19.006)
Neyal, Nur , Atkinson, E. C., Tarlton, Caitlin, Schwarz, Christopher, Decker, Paul, Kosel, Matthew, Son, Jiye , Keegan, Mark , Kantarci, Kejal, Kantarci, Orhun, Tobin, W., Aboseif, Albert , Atkinson, Elizabeth, Jackson-Tarlton, Caitlin S. , Schwarz, Christopher, Kosel, Matthew , Kantarci, Kejal , Kantarci, O, Zeydan, Burcu

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217162 Get It

Impact of MRI Activity and Medical Comorbidities on Serum Neurofilament Light Chain in Multiple Sclerosis (P3-20.004)
Chouhdry, Hira , Schleiss, Katherine, Baker, Matthew , Morris, Pearse, Tobin, W., Flanagan, Eoin , Kantarci, OH , Keegan, Mark , Soldan, M. Paz, Pittock, Sean, banks, Samantha, Flanagan, Eoin P. , Kantarci, Orhun H. , Soldán, M. Mateo Paz , Pittock, Sean J.

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215939 Get It

B109-09 Multi-Trait Polygenic Scores for COPD and COPD Exacerbations Implicate Druggable Proteins
Zhang, C , Konigsberg, I R, He, Y, Zhang, J, Chikowore, T, Feldman, W B, Hu, X, Ding, Y, Pasaniuc, B, Chang, D, Chen, Q, Lasky-Su, J A, Hecker, J, Tobin, M D, Chen, J, Kalra, S, Pratte, K A, Im, H K , Wan, E S, Manichaikul, A W, Silverman, E K, Bowler, R P, Lange, L A, Ortega, V E, Martin, A R, Cho, M H, Moll, M R, Konigsberg, Iain R. , Paşaniuc, Bogdan , Lasky‐Su, Jessica , Kalra, S. , Pratte, K.A., Wan, Emily S. , Silverman, Edwin K. , Bowler, R P, Moll, Matthew

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.1934 Get It

Abstract Rationale To construct multi-trait polygenic scores (PRS) predicting chronic obstructive pulmonary disease (COPD) and exacerbations, validate their performance in diverse cohorts, and identify PRS-related proteins for potential therapeutic targeting. Methods PRSmix+, a multi-trait PRS framework, is used to train a composite PRS (PRSmulti) in COPDGene non-Hispanic white participants (n = 6,647). Associations of PRSmulti with COPD status (GOLD 2-4 vs. GOLD 0 or ICD) and exacerbation frequency were tested in COPDGene African American (n = 2,466), ECLIPSE (n = 1,858), MassGeneral Brigham Biobank (n = 15,152), and All of Us (n = 118,566). Protein prediction models were applied to GWAS summary statistics from traits contributing to PRSmulti and were validated with proteomic data in COPDGene (n = 5,173) and UK Biobank (n = 5,012). Results PRSmix+ selected 7 traits for PRSmulti. In multivariable models, PRSmulti was associated with COPD status (meta-analysis random effects (RE) OR 1.58 [95% CI: 1.28-1.94]) and exacerbation frequency (meta-analysis RE beta 0.21 [95% CI: 0.11-0.31]), with higher effect sizes observed in smoking-enriched cohorts. PRSmulti outperformed traditional single-trait PRS in all tested cohorts. Using protein prediction models, we identified 73 proteins associated with the PRS that were also validated with measured protein levels in COPDGene and UK biobank. Of these proteins, 25 were linked to approved or investigational drugs. Notable targets include AGER (RAGE), IL1RL1, and SCARF2, all implicated in COPD pathogenesis and exacerbations. Conclusions Multi-trait PRS improves prediction of COPD and exacerbation risk. Integration with proteomic data identifies druggable protein targets, offering a promising avenue for precision medicine in COPD management. Trial registration. COPDGene: NCT00608764; ECLIPSE: NCT00292552. This abstract is funded by: NIH and the COPD Foundation
MRI Deep Learning for Differentiating Glioblastoma, IDH Wild-type from Central Nervous System Diffuse Large B-cell Lymphoma
Moassefi, Mana , Decker, Paul A. , Conte, Gian Marco , Kosel, Matthew L., Molinaro, Annette M. , Niederschweiberer, Moritz , Nikanpour, Yalda , Ruff, Michael W. , Burns, Terry C. , Farooq, Umar , Derdeyn, C, Jenkins, RB , Lachance, Daniel H , Eckel‐Passow, Jeanette E. , Kosel, Matthew , Niederschweiberer, Moritz A , Derdeyn, Colin P , Habermann, Thomas , Cerhan, James R , Greenlee, Jeremy D W , Howard, Matthew A , Slager, Susan L , Vaubel, Rachael A , Lachance, Daniel , Erickson, Bradley J , Tobin, W Oliver , Eckel-Passow, Jeanette E , Farooq, Umar , Conte, Gian Marco , Burns, Terry C , Moassefi, Mana , Decker, Paul A. , Kosel, Matthew , Molinaro, Annette M. , Derdeyn, Colin P. , Habermann, Thomas M. , Cerhan, James R. , Greenlee, Jeremy D.W. , Howard, Matthew A. , Slager, Susan L. , Vaubel, Rachael A. , Jenkins, Robert B. , Erickson, Bradley J.

Mayo Clinic

Cancer Research Communications | May 4, 2026 | Volume: 6 | Issue: 5 | Pages: 1168-1179

10.1158/2767-9764.crc-25-0710 | PMID 42081255 Get It

Abstract Glioblastoma (GBM), isocitrate dehydrogenase wild-type (IDHwt) and central nervous system diffuse large B-cell lymphoma (CNS-DLBCL) are aggressive brain tumors with overlapping MRI features, yet distinct treatment approaches. Noninvasive tools are needed to aid in differential diagnosis. Deep learning on T1 postcontrast and T2-weighted MRI sequences were used to differentiate GBM and CNS-DLBCL. A three-stage temporal study design was utilized. Model development was performed on 146 patients with CNS-DLBCL and 146 age-matched, sex-matched, and MRI year–matched patients with GBM diagnosed at Mayo Clinic between 1998 and 2019. Models were tested on independent temporal test cohorts. Initial testing included 240 independent GBM diagnosed at Mayo Clinic between 1998 and 2019. The prospective test cohort included 37 patients with CNS-DLBCL and 256 patients with GBM diagnosed at Mayo Clinic after January 1, 2020, and 36 patients with CNS-DLBCL diagnosed at an external institution. Of the patients diagnosed at Mayo Clinic, 47% had MRIs generated from non-Mayo institutions. Two different model approaches were compared: (i) ensemble approach using area under the receiver operating characteristic curve (AUC) and cross-validation for model selection and (ii) loss approach minimizing cross-entropy loss and cross-validation to evaluate prediction performance. The AUCs on the prospective test cohort were 0.84 [95% confidence interval (CI), 0.78–0.90] and 0.83 (95% CI, 0.77–0.88) for the ensemble and loss approaches, respectively. Stability of ensemble prediction improved with the increasing number of models. Stratified AUC analysis demonstrated consistent performance across sex and age. We utilized a robust temporal study design and applied 2 different analytic approaches to develop a classification model. The findings confirm the feasibility of using MRI-based deep learning models to differentiate GBM from CNS-DLBCL. Significance: GBM, IDHwt and CNS-DLBCL are aggressive brain tumors with overlapping MRI features, yet distinct treatment approaches. Noninvasive tools are needed to aid in differential diagnosis. We developed MRI-based deep learning models to differentiate GBM, IDHwt from CNS-DLBCL using a rigorous three-stage temporal design that included prospective validation. The model AUC on a prospective cohort was 0.84.
Percutaneous spinal stimulation to enhance gait and alleviate functional impairments in multiple sclerosis: A pilot study
Jahanian, Omid , Asp, Anders J., Gill, Megan L., Veith, Daniel D. , Fernandez, K. A. , Hogen, Cecilia A., Mills, Candee J. , Thoreson, Andrew R. , Grahn, Peter J. , Fernandez, Katrina A, Tobin, W Oliver , Fernandez, K A , Jahanian, Omid , Asp, Anders J., Solinsky, Ryan , Kaufman, Kenton R. , Zhao, Kristin D. , Tobin, W. Oliver

Mayo Clinic

Multiple Sclerosis Journal – Experimental, Translational and Clinical | April 29, 2026 | Volume: 12 | Issue: 2 | Pages: No page available

10.1177/20552173261432301 | PMID 42112095 Get It

Objective To evaluate the feasibility and potential efficacy of percutaneous spinal stimulation (epidural stimulation, ES) combined with task-specific training to reduce spasticity and improve gait and balance in individuals with progressive multiple sclerosis (MS). Methods Two men with progressive MS (EDSS 6.5) underwent ES lead implantation targeting the lower spinal cord, followed by one month of rehabilitation involving 12 ES-assisted training sessions. Assessments included instrumented gait analysis, Modified Ashworth Scale (MAS), pendulum test, and static balance testing performed at baseline, and at end of the study with ES-Off and ES-On conditions. Results Participant 1, with spastic hemiparetic gait, demonstrated improved lower extremity joint kinematics and muscle activation during gait, reduced knee extensor spasticity, and enhanced functional movement patterns with ES-On. Participant 2, with significant paraparesis and minimal spasticity, showed limited gait changes but experienced marked improvements in static balance, particularly under eyes-closed conditions. No adverse events were reported. Conclusion This pilot study demonstrates the feasibility and tolerability of ES paired with task-specific training in progressive MS. Participant-specific responses were observed, including improvements in gait kinematics, neuromuscular activation, spasticity, or balance; however, spatiotemporal gait parameters did not improve. These preliminary findings highlight response heterogeneity and the need for individualized ES parameter tuning. Trial registry name and URL: https://clinicaltrials.gov/study/NCT06019611
Psychiatric comorbidities cluster early after onset in MOGAD: a cross-sectional comparative study with MS and NMOSD
Niederschweiberer, Moritz , Bakir, Çiçek Nur, Cacciaguerra, Laura , Tillema, Jan-Mendelt, Vilaseca, Andreu, Thakolwiboon, Smathorn , Aboseif, Albert , Syc-Mazurek, Stephanie B., Rees, William A. , Lopez-Chiriboga, A Sebastian, Wingerchuk, Dean M, Croarkin, P., Sagen, Jessica, Chen, John J, Bakir, Cicek, Cacciaguerra, Laura , Thakolwiboon, Smathorn , Aboseif, Albert , Syc-Mazurek, Stephanie B , Basso, Michael R. , Tobin, W Oliver , Pittock, S J , Flanagan, E P , Niederschweiberer, Moritz A , Bakır, Çiçek Nur , Vorasoot, Nisa , Tillema, Jan‐Mendelt , Vilaseca, Andreu , Syc‐Mazurek, Stephanie B. , López‐Chiriboga, A. Sebastian , Wingerchuk, Dean M. , Tobin, W. Oliver , Croarkin, Paul E. , Pittock, Sean J. , Flanagan, Eoin P.

Mayo Clinic

Journal of Neurology, Neurosurgery & Psychiatry | April 9, 2026 | Volume: 97 | Issue: 9 | Pages: 817-826

10.1136/jnnp-2025-338335 | PMID 41956817 Get It

Background Psychiatric comorbidities are increasingly recognised in demyelinating diseases, yet their frequency and timing in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are not well defined. We aimed to characterise the spectrum and temporal pattern of psychiatric illness in MOGAD and compare to multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) with aquaporin-4 antibody (AQP4-IgG). Methods We conducted a cross-sectional study of patients with MOGAD (n=388), age-matched and sex-matched MS (n=257) and AQP4-IgG-positive NMOSD (n=58) evaluated at Mayo Clinic (1991–2025). Psychiatric diagnoses, timing relative to the first attack and patient-reported outcomes were extracted from electronic health records (EHRs). Complementary analyses were conducted using the NeuroBlu real-world EHR database. Results Among 388 patients with MOGAD, 54.8% had ≥1 psychiatric disorder, most commonly anxiety (47.7%), depression (36.6%) and attention-deficit/hyperactivity disorder (ADHD, 9%). After the first attack, 33.3% of patients with MOGAD developed a new psychiatric disorder, often within the first year. MOGAD showed a lower frequency of depression versus MS (36.6% vs 47.5%, p=0.02) but similar rates of anxiety and ADHD. Temporal patterns differed: psychiatric disorders often appeared years before onset in MS but clustered shortly after onset in MOGAD. NeuroBlu analyses supported high rates of psychiatric disorders across the three conditions. Conclusion Psychiatric comorbidities are common in MOGAD, particularly depression and anxiety, typically emerging close after onset, whereas in MS they often preceded onset by years. These findings underscore the need for routine psychiatric screening in MOGAD and highlight unresolved questions regarding whether, and to what extent, MOG-IgG-mediated inflammatory demyelination contributes to psychiatric vulnerability.
Multi-trait polygenic scores for COPD and COPD exacerbations implicate druggable proteins
Zhang, Chengyue , He, Yixuan, Zhang, Jingzhou, Feldman, William B. , Ding, Yi , Pasaniuc, Bogdan, Chang, Diana, Chen, Qingwen , Lasky-Su, Jessica, Hecker, Julian, Tobin, Martin D., Chen, Jing , Kalra, S. , Pratte, Katherine A., Im, Hae Kyung, Wan, Emily S., Manichaikul, Ani, Silverman, Edwin K., Bowler, Russell P., Lange, Leslie A., Ortega, Victor E., Cho, Michael H., Moll, Matthew R., Konigsberg, Iain R. , Zhang, Jingzhou , Chikowore, Tinashe , Hu, Xiaowei , Paşaniuc, Bogdan , Lasky‐Su, Jessica , Tobin, Martin D. , Pratte, Katherine , Wan, Emily S. , Manichaikul, Ani , Silverman, Edwin K. , Bowler, Russell P. , Lange, Leslie A., Ortega, Victor E. , Martin, Alicia R. , Cho, Michael H. , Moll, Matt

Mayo Clinic

JCI Insight | February 19, 2026 | Volume: 11 | Issue: 7 | Pages: No page available

10.1172/jci.insight.199951 | PMID 41712304 Get It

BACKGROUND We constructed multi-trait polygenic risk scores (PRSs) predicting chronic obstructive pulmonary disease (COPD) and exacerbations, validated their performance in diverse cohorts, and identified PRS-related proteins for potential therapeutic targeting. METHODS PRSmix + , a multi-trait PRS framework, is used to train a composite PRS (PRS multi ) in COPDGene non-Hispanic White participants ( n = 6,647). Associations of PRS multi with COPD status (GOLD 2–4 vs. GOLD 0 or ICD) and exacerbation frequency were tested in COPDGene African American ( n = 2,466), ECLIPSE ( n = 1,858), Mass General Brigham Biobank ( n = 15,152), and All of Us ( n = 118,566). Protein prediction models were applied to GWAS summary statistics from traits contributing to PRS multi and were validated with proteomic data in COPDGene ( n = 5,173) and UK Biobank ( n = 5,012). RESULTS PRSmix + selected 7 traits for PRS multi . In multivariable models, PRS multi was associated with COPD status (meta-analysis random effects [RE] OR 1.58 [95% CI: 1.28–1.94]) and exacerbation frequency (meta-analysis RE β 0.21 [95% CI: 0.11–0.31]), with higher effect sizes observed in smoking-enriched cohorts. PRS multi outperformed traditional single-trait PRS in all tested cohorts. Using protein prediction models, we identified 73 proteins associated with the PRSs that were also validated with measured protein levels in COPDGene and UK Biobank. Of these proteins, 25 were linked to approved or investigational drugs. Notable targets include RAGE/sRAGE, IL1RL1, and SCARF2, all implicated in COPD pathogenesis and exacerbations. CONCLUSIONS Multi-trait PRS improves prediction of COPD and exacerbation risk. Integration with proteomic data identifies druggable protein targets, offering a promising avenue for precision medicine in COPD management. TRIAL REGISTRATION COPDGene: ClinicalTrials.gov NCT00608764; ECLIPSE: ClinicalTrials.gov NCT00292552.